Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories

Share:

 
 

Nathan Shumway, D.O., FACP

Nathan Shumway, D.O., FACP

Provider Type: Physician

Specialties:
  • Hematology
  • Medical Oncology
Board Certifications:
  • Medical Oncology
  • Hematology

General Summary

Dr. Shumway is an experienced medical oncologist and hematologist with demonstrated history of working in federal, community, academic and private health care sectors. He has expertise in internal medicine and clinical research with an emphasis on breast cancer immunotherapy, colon cancer and benign hematology.

Education

  • Fellowship in Hematology and Medical Oncology (2008)
    San Antonio Uniformed Services Health Education Consortium, Brooke Army Medical Center, San Antonio, TX
  • Residency in Internal Medicine (2005)
    Walter Reed Army Medical Center, Washington, D.C.
  • Internship in Internal Medicine (2003)
    Walter Reed Army Medical Center, Washington, D.C.
  • Medical Doctorate (2002)
    Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, Pomona, CA

Research Interest

Breast cancer immunotherapy; colorectal cancer; benign hematology; medical education

Medical Practice

Program Director, Hematology & Oncology Fellowship, San Antonio Military Medical Center, Rank: LTC (May 2012 – September 2015)

Other Information

Dr. Shumway is married to Judy Shumway, D.O., M.P.H., a hospitalist in San Antonio. They have 2 sons.

Publications

Show all Publications
  • Efficacy of Booster Inoculations in a Phase II Trial of GP2, a HER2-Derived Peptide Vaccine, for the Prevention of Breast Cancer Recurrence

    Annals of Surgical Oncology, 2016

  • Impact of Boosting in the Phase II Trial of the AE37+ GM-CSF Vaccine in High-risk Breast Cancer Patients to Prevent Recurrence

    Annals of Surgical Oncology, 2016

  • Use of milestones and development of entrustable professional activities in 2 hematology/oncology training programs

    Journal of Graduate Medical Education, 2015

  • A randomized pilot study comparing olanzapine (Zyprexa) to aprepitant (Emend) for treatment of chemotherapy-induced nausea and vomiting

    Journal of Pain Management, 2015

  • Correlation of peripheral blood smear review and bone marrow biopsies for benign hematology Outpatient referrals.

    ASCO Annual Meeting Proceedings, 2015

  • Final pre-specified analysis of the phase II trial of the AE37+ GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.

    ASCO Annual Meeting Proceedings, 2015

  • Peripheral Blood Smear Utilization within a Military Hematology/Oncology Fellowship Program

    Blood, 2014

  • Informed consent training for medical oncology fellows: Checklist-based simulation exercise.

    ASCO Annual Meeting Proceedings, 2014

  • Chemotherapy infusion reaction training for medical oncology fellows: A checklist-based simulation exercise.

    ASCO Annual Meeting Proceedings, 2014

  • Current approaches and challenges in monitoring treatment responses in breast cancer

    Journal of Cancer, 2014

  • Current approaches and challenges in early detection of breast cancer recurrence

    Journal of Cancer, 2014

  • Future directions for monitoring treatment responses in breast cancer

    Journal of Cancer, 2014

  • Future directions for the early detection of recurrent breast cancer

    Journal of Cancer, 2014

  • Primary analysis of the prospective, randomized, phase II trial of GP2+ GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients

    ASCO Annual Meeting Proceedings, 2014

  • Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.

    ASCO Annual Meeting Proceedings, 2014

  • Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

    ASCO Annual Meeting Proceedings, 2014

  • Use Of Milestones And Development Of Entrustable Professional Activities (EPAs) In Hematology/Oncology (HO) Training Programs -- A Proactive And Practical Approach to a New Evaluation System.

    Accreditation Council of Graduate Medical Education, 2014

  • Use of an Attenuated Version of a Strongly Immunogenic, Peptide-based Vaccine to Enhance an Anti-cancer Immune Response against Folate Receptor-alpha (FR alpha)

    Annals Of Surgical Oncology, 2013

  • Abstract P4-13-05: HLA-A2 is not a prognostic indicator in breast cancer: Implications for cancer vaccine trials

    Cancer Research, 2013

  • Use of an attenuated version of a strongly immunogenic, peptide-based vaccine to enhance an anti-cancer immune response against folate receptor-alpha.

    Cancer Research, 2013

  • Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence

    Cancer Research, 2013

  • Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients

    Cancer Research, 2013

  • Safety and efficacy of the HER2-derived GP2 peptide vaccine in combination with trastuzumab for breast cancer patients in the adjuvant setting.

    ASCO Annual Meeting Proceedings, 2013

  • Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence.

    ASCO Annual Meeting Proceedings, 2013

  • Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients.

    Journal for Immunotherapy of Cancer, 2013

  • Prospective survey study regarding the implementation of new communication skills curriculum for medical oncology trainees.

    ASCO Annual Meeting Proceedings, 2012

  • An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.

    ASCO Annual Meeting Proceedings, 2012

  • Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer.

    ASCO Annual Meeting Proceedings, 2012

  • Safety and long-term maintenance of anti-HER2 immunity following booster inoculations of the E75 breast cancer vaccine.

    ASCO Annual Meeting Proceedings, 2012

  • Cancer vaccines: should we be targeting patients with less aggressive disease?

    Expert Review of Vaccines, 2012

  • Trends in Circulating Tumor Cells (CTCS) in Multiple Adjuvant (ADJ) Trials of HER2-Specific Peptide Vaccines (PV) in Breast Cancer (BRCA) PTS

    Journal of Immunotherapy, 2012

  • From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines.

    ASCO Annual Meeting Proceedings, 2012

  • The combination of trastuzumab and HER2-directed peptide vaccines is safe in HER2-expressing breast cancer patients

    Cancer Research, 2012

  • Abstract LB-218: Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine

    American Association for Cancer Research AACR, 2012

  • Immune reconstitution after chemotherapy correlates with increased in vitro immune response in breast cancer patients undergoing peptide vaccine therapy

    Cancer Research, 2012

  • Abstract LB-218: Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine

    Cancer Research, 2012

  • Abstract P2-11-01: Final pre-specified analysis of the phase II trial of the GP2+ GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence

    Cancer Research, 2012

  • Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.

    ASCO Annual Meeting Proceedings, 2011

  • Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER2/neu peptide vaccine trial.

    ASCO Annual Meeting Proceedings, 2011

  • AE37: a novel T-cell-eliciting vaccine for breast cancer

    Expert Opinion on Biological Therapy, 2011

  • Advances in the Management of Triple Negative Breast Cancer Ch.9: Targeted therapies: other agents in clinical trials

    Advances in the Management of Triple Negative Breast Cancer, 2011

  • Therapeutic Breast Cancer Vaccines

    BioDrugs, 2009

  • A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting

    ASCO Annual Meeting Proceedings, 2009

  • Optical density values correlate with the clinical probability of heparin induced thrombocytopenia

    Journal of Thrombosis and Thrombolysis, 2008

  • Presence and treatment of air hunger in severely ill patients

    Respiratory Medicine, 2008

  • Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis

    Archives of Internal Medicine, 2006

  • Hematology Consultation along with the 4 T’s Clinical Scoring System Improves the Evaluation and Management of Heparin Induced Thrombocytopenia.

    Blood, 2004

  • Treating Air Hunger at End-of-Life

    CHEST Journal, 2004

  • Prospective Observation of Air Hunger in Severely Ill Patients

    CHEST Journal, 2004

  • Treatment of air hunger at end of life

    American Thoracic Society ATS, 2002

Accolades & Memberships

  • American College of Physicians
  • American Osteopathic Association
  • American Society of Clinical Oncology
  • American Society of Hematology
  • ASCO Connection, Fellow and Early-Career Oncologist edition (July 2014), 2 page feature article titled "Career Paths: Interview with a Physician Educator" (2014)
  • ASCO University/E-Learning, Editorial Board Member (2014 – present)
  • Co-Chair, Annual Baptist Cancer Update (Feb 2016 – present)
  • Co-Founder, San Antonio Uniformed Services Health Education
  • Consortium (SAUSHEC) LEAD, 501(c)(3) organization (2016 – present)
  • Most Valuable Teacher Award, Uniformed Services University High School (2008 – 2012)
  • Texas Medical Association, Committee on Cancer member (May 2017 – Sep 2020)
  • Texas Oncology, Advance Practice Provider (APP) Executive Committee (2015 – present)
  • Uniformed Services University High School, Department of Medicine, James J Leonard Award for academic year 2011–2012 (Best Teaching Ambulatory Staff)

Military Awards

  • Airbone Wings (1995)
  • Army Achievement Medal (AAM) (1997)
  • Army Achievement Medal (AAM) (2003 – 2005)
  • Army Achievement Medal (AAM) x 2 (2002)
  • Army Commendation Medal (ARCOM) (2005)
  • Army Commendation Medal (ARCOM) (2008)
  • Army Commendation Medal (ARCOM) (2010)
  • Army Service Ribbon (ASR) (2002)
  • Army Superior Unit Award (ASUA) (2005)
  • Global War on Terrorism Service Medal (GWOT) (2010)
  • Iraq Campaign Medal (ICMCS) x 2 (2010)
  • Meritorious Unit Commendation (MUC) (2008)
  • National Defense Service Ribbon (NDSM) (2002)